Header Logo

Connection

GUNAR K ZAGARS to Prostatic Neoplasms

Back to Details
This is a "connection" page, showing publications GUNAR K ZAGARS has written about Prostatic Neoplasms.
GUNAR K ZAGARS
Connection Strength
2.126
Prostatic Neoplasms
  1. Impact of androgen deprivation therapy on survival in men treated with radiation for prostate cancer. Urology. 2002 Sep; 60(3 Suppl 1):22-30; discussion 30-1.
    View in: PubMed
    Score: 0.063
  2. Addition of radiation therapy to androgen ablation improves outcome for subclinically node-positive prostate cancer. Urology. 2001 Aug; 58(2):233-9.
    View in: PubMed
    Score: 0.058
  3. Conventional external-beam radiation therapy alone or with androgen ablation for clinical stage III (T3, NX/N0, M0) adenocarcinoma of the prostate. Int J Radiat Oncol Biol Phys. 1999 Jul 01; 44(4):809-19.
    View in: PubMed
    Score: 0.050
  4. Relationship of ultrasound staging and bilateral biopsy positivity to outcome in stage T1c prostate cancer treated with radiotherapy. Urology. 1998 Oct; 52(4):647-52.
    View in: PubMed
    Score: 0.048
  5. Prostate cancer in African-American men: outcome following radiation therapy with or without adjuvant androgen ablation. Int J Radiat Oncol Biol Phys. 1998 Oct 01; 42(3):517-23.
    View in: PubMed
    Score: 0.048
  6. Regarding Zagars and Pollack. Int J Radiat Oncol Biol Phys. 1998 Jul 01; 41(4):973-4.
    View in: PubMed
    Score: 0.047
  7. Late effects after radiotherapy for prostate cancer in a randomized dose-response study: results of a self-assessment questionnaire. Urology. 1998 Jun; 51(6):991-7.
    View in: PubMed
    Score: 0.047
  8. Androgen ablation in addition to radiation therapy for prostate cancer: is there true benefit? Semin Radiat Oncol. 1998 Apr; 8(2):95-106.
    View in: PubMed
    Score: 0.046
  9. External beam radiotherapy for stage T1/T2 prostate cancer: how does it stack up? Urology. 1998 Feb; 51(2):258-64.
    View in: PubMed
    Score: 0.046
  10. External beam radiotherapy dose response of prostate cancer. Int J Radiat Oncol Biol Phys. 1997 Dec 01; 39(5):1011-8.
    View in: PubMed
    Score: 0.045
  11. Kinetics of serum prostate-specific antigen after external beam radiation for clinically localized prostate cancer. Radiother Oncol. 1997 Sep; 44(3):213-21.
    View in: PubMed
    Score: 0.044
  12. Management of unfavorable locoregional prostate carcinoma with radiation and androgen ablation. Cancer. 1997 Aug 15; 80(4):764-75.
    View in: PubMed
    Score: 0.044
  13. Serum testosterone levels after external beam radiation for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys. 1997 Aug 01; 39(1):85-9.
    View in: PubMed
    Score: 0.044
  14. Prostate-specific antigen cancer volume: a significant prognostic factor in prostate cancer patients at intermediate risk of failing radiotherapy. Int J Radiat Oncol Biol Phys. 1997 May 01; 38(2):327-33.
    View in: PubMed
    Score: 0.043
  15. Prognostic factors for clinically localized prostate carcinoma: analysis of 938 patients irradiated in the prostate specific antigen era. Cancer. 1997 Apr 01; 79(7):1370-80.
    View in: PubMed
    Score: 0.043
  16. Serum testosterone--a significant determinant of metastatic relapse for irradiated localized prostate cancer. Urology. 1997 Mar; 49(3):327-34.
    View in: PubMed
    Score: 0.043
  17. Radiotherapy vs. surgery for prostate cancer: an age old question. Int J Radiat Oncol Biol Phys. 1996 May 01; 35(2):407-9.
    View in: PubMed
    Score: 0.040
  18. Radiotherapy for regionally localized hormone refractory prostate cancer. Int J Radiat Oncol Biol Phys. 1995 Nov 01; 33(4):907-12.
    View in: PubMed
    Score: 0.039
  19. Prostate cancer and radiation therapy--the message conveyed by serum prostate-specific antigen. Int J Radiat Oncol Biol Phys. 1995 Aug 30; 33(1):23-35.
    View in: PubMed
    Score: 0.039
  20. Prostate-specific antigen and radiation therapy for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys. 1995 May 15; 32(2):293-306.
    View in: PubMed
    Score: 0.038
  21. The source of pretreatment serum prostate-specific antigen in clinically localized prostate cancer--T, N, or M? Int J Radiat Oncol Biol Phys. 1995 Apr 30; 32(1):21-32.
    View in: PubMed
    Score: 0.038
  22. Radiation therapy for T1 and T2 prostate cancer: prostate-specific antigen and disease outcome. Urology. 1995 Mar; 45(3):476-83.
    View in: PubMed
    Score: 0.037
  23. Gleason grade and other prognostic factors--response to Drs. Hammond and Grignon. Int J Radiat Oncol Biol Phys. 1995 Jan 15; 31(2):435.
    View in: PubMed
    Score: 0.037
  24. The prognostic importance of Gleason grade in prostatic adenocarcinoma: a long-term follow-up study of 648 patients treated with radiation therapy. Int J Radiat Oncol Biol Phys. 1995 Jan 15; 31(2):237-45.
    View in: PubMed
    Score: 0.037
  25. Influence of radiotherapy on node-positive prostate cancer treated with androgen ablation. Int J Radiat Oncol Biol Phys. 1995 Jan 01; 31(1):13-9.
    View in: PubMed
    Score: 0.037
  26. Neutron therapy in prostate cancer--is the therapeutic ratio improved? Int J Radiat Oncol Biol Phys. 1995 Jan 01; 31(1):204-5.
    View in: PubMed
    Score: 0.037
  27. Prostate specific antigen as an outcome variable for T1 and T2 prostate cancer treated by radiation therapy. J Urol. 1994 Nov; 152(5 Pt 2):1786-91.
    View in: PubMed
    Score: 0.036
  28. Early androgen ablation for stage D1 (N1 to N3, M0) prostate cancer: prognostic variables and outcome. J Urol. 1994 May; 151(5):1330-3.
    View in: PubMed
    Score: 0.035
  29. The T classification of clinically localized prostate cancer. An appraisal based on disease outcome after radiation therapy. Cancer. 1994 Apr 01; 73(7):1904-12.
    View in: PubMed
    Score: 0.035
  30. The prognostic significance of DNA ploidy in clinically localized prostate cancer treated with radiation therapy. Int J Radiat Oncol Biol Phys. 1994 Mar 01; 28(4):821-8.
    View in: PubMed
    Score: 0.035
  31. The serum prostate-specific antigen level three months after radiotherapy for prostate cancer: an early indicator of response to treatment. Radiother Oncol. 1994 Feb; 30(2):121-7.
    View in: PubMed
    Score: 0.035
  32. Serum PSA as a tumor marker for patients undergoing definitive radiation therapy. Urol Clin North Am. 1993 Nov; 20(4):737-47.
    View in: PubMed
    Score: 0.034
  33. Prognostic factors in prostate cancer. Analysis of 874 patients treated with radiation therapy. Cancer. 1993 Sep 01; 72(5):1709-25.
    View in: PubMed
    Score: 0.034
  34. The prognostic significance of a single serum prostate-specific antigen value beyond six months after radiation therapy for adenocarcinoma of the prostate. Int J Radiat Oncol Biol Phys. 1993 Sep 01; 27(1):39-45.
    View in: PubMed
    Score: 0.034
  35. The fall and rise of prostate-specific antigen. Kinetics of serum prostate-specific antigen levels after radiation therapy for prostate cancer. Cancer. 1993 Aug 01; 72(3):832-42.
    View in: PubMed
    Score: 0.033
  36. Prostate-specific antigen. An important marker for prostate cancer treated by external beam radiation therapy. Cancer. 1993 Jul 15; 72(2):538-48.
    View in: PubMed
    Score: 0.033
  37. Radiotherapy versus surgery for stage C prostate cancer. Urology. 1993 Jun; 41(6):605.
    View in: PubMed
    Score: 0.033
  38. In regard to Pollack et al., prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. IJROBP 2002;53:1097-1105. Int J Radiat Oncol Biol Phys. 2003 Apr 01; 55(5):1461; author reply 1461-2.
    View in: PubMed
    Score: 0.033
  39. A commentary on dose escalation and bNED in prostate cancer. Int J Radiat Oncol Biol Phys. 2003 Mar 15; 55(4):1151; author reply 1151-2.
    View in: PubMed
    Score: 0.033
  40. Prostate-specific antigen as a prognostic factor for prostate cancer treated by external beam radiotherapy. Int J Radiat Oncol Biol Phys. 1992; 23(1):47-53.
    View in: PubMed
    Score: 0.030
  41. The influence of local control on metastatic dissemination of prostate cancer treated by external beam megavoltage radiation therapy. Cancer. 1991 Dec 01; 68(11):2370-7.
    View in: PubMed
    Score: 0.030
  42. Prostate-specific antigen and external beam radiation therapy in prostate cancer. Cancer. 1991 Jan 15; 67(2):412-20.
    View in: PubMed
    Score: 0.028
  43. The influence of pelvic node irradiation on prognosis. Int J Radiat Oncol Biol Phys. 1989 Mar; 16(3):882.
    View in: PubMed
    Score: 0.025
  44. Adjuvant estrogen following radiation therapy for stage C adenocarcinoma of the prostate: long-term results of a prospective randomized study. Int J Radiat Oncol Biol Phys. 1988 Jun; 14(6):1085-91.
    View in: PubMed
    Score: 0.023
  45. The role of radiation therapy in stages A2 and B adenocarcinoma of the prostate. Int J Radiat Oncol Biol Phys. 1988 Apr; 14(4):701-9.
    View in: PubMed
    Score: 0.023
  46. Stage C adenocarcinoma of the prostate. An analysis of 551 patients treated with external beam radiation. Cancer. 1987 Oct 01; 60(7):1489-99.
    View in: PubMed
    Score: 0.022
  47. Quality-of-life questionnaire results 2 and 3 years after radiotherapy for prostate cancer in a randomized dose-escalation study. Urology. 2003 Oct; 62(4):707-13.
    View in: PubMed
    Score: 0.017
  48. Molecular markers of outcome after radiotherapy in patients with prostate carcinoma: Ki-67, bcl-2, bax, and bcl-x. Cancer. 2003 Apr 01; 97(7):1630-8.
    View in: PubMed
    Score: 0.016
  49. Prostate biopsy status and PSA nadir level as early surrogates for treatment failure: analysis of a prostate cancer randomized radiation dose escalation trial. Int J Radiat Oncol Biol Phys. 2002 Nov 01; 54(3):677-85.
    View in: PubMed
    Score: 0.016
  50. Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys. 2002 Aug 01; 53(5):1097-105.
    View in: PubMed
    Score: 0.016
  51. Ki-67 staining is an independent correlate of biochemical failure in prostate cancer treated with radiotherapy. Clin Cancer Res. 2002 May; 8(5):1148-54.
    View in: PubMed
    Score: 0.015
  52. Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer. J Clin Oncol. 2000 Dec 01; 18(23):3904-11.
    View in: PubMed
    Score: 0.014
  53. Complications from radiotherapy dose escalation in prostate cancer: preliminary results of a randomized trial. Int J Radiat Oncol Biol Phys. 2000 Oct 01; 48(3):635-42.
    View in: PubMed
    Score: 0.014
  54. The early supra-additive apoptotic response of R3327-G prostate tumors to androgen ablation and radiation is not sustained with multiple fractions. Int J Radiat Oncol Biol Phys. 2000 Jan 01; 46(1):153-8.
    View in: PubMed
    Score: 0.013
  55. Relationship of Ki-67 labeling index to DNA-ploidy, S-phase fraction, and outcome in prostate cancer treated with radiotherapy. Prostate. 1999 Nov 01; 41(3):166-72.
    View in: PubMed
    Score: 0.013
  56. Transrectal ultrasound for staging prostate carcinoma prior to radiation therapy: an evaluation based on disease outcome. Cancer. 1999 Apr 01; 85(7):1577-85.
    View in: PubMed
    Score: 0.012
  57. Prostate cancer treatment with radiotherapy: maturing methods that minimize morbidity. Semin Oncol. 1999 Apr; 26(2):150-61.
    View in: PubMed
    Score: 0.012
  58. Familial prostate cancer: outcome following radiation therapy with or without adjuvant androgen ablation. Int J Radiat Oncol Biol Phys. 1999 Jan 15; 43(2):379-83.
    View in: PubMed
    Score: 0.012
  59. Prostate target volume variations during a course of radiotherapy. Int J Radiat Oncol Biol Phys. 1998 Oct 01; 42(3):661-72.
    View in: PubMed
    Score: 0.012
  60. Supraadditive apoptotic response of R3327-G rat prostate tumors to androgen ablation and radiation. Int J Radiat Oncol Biol Phys. 1997 Jul 15; 38(5):1071-7.
    View in: PubMed
    Score: 0.011
  61. Quiescence in R3327-G rat prostate tumors after androgen ablation. Cancer Res. 1997 Jun 15; 57(12):2493-500.
    View in: PubMed
    Score: 0.011
  62. The significance of DNA-ploidy and S-phase fraction in node-positive (stage D1) prostate cancer treated with androgen ablation. Prostate. 1997 Apr 01; 31(1):21-8.
    View in: PubMed
    Score: 0.011
  63. Prostate specific antigen density as a prognostic factor for patients with prostate carcinoma treated with radiotherapy. Cancer. 1996 Apr 15; 77(8):1515-23.
    View in: PubMed
    Score: 0.010
  64. Conventional vs. conformal radiotherapy for prostate cancer: preliminary results of dosimetry and acute toxicity. Int J Radiat Oncol Biol Phys. 1996 Feb 01; 34(3):555-64.
    View in: PubMed
    Score: 0.010
  65. Radiotherapy and androgen ablation for clinically localized high-risk prostate cancer. Int J Radiat Oncol Biol Phys. 1995 Apr 30; 32(1):13-20.
    View in: PubMed
    Score: 0.009
  66. Frequency and characterization of p53 mutations in clinically localized prostate cancer. Urology. 1995 Mar; 45(3):470-5.
    View in: PubMed
    Score: 0.009
  67. Local treatment for prostate cancer: 90 years later--response to M. V. Pilepich. Int J Radiat Oncol Biol Phys. 1995 Jan 15; 31(2):436.
    View in: PubMed
    Score: 0.009
  68. Significance of tumor angiogenesis in clinically localized prostate carcinoma treated with external beam radiotherapy. Urology. 1994 Dec; 44(6):869-75.
    View in: PubMed
    Score: 0.009
  69. Relationship of tumor DNA-ploidy to serum prostate-specific antigen doubling time after radiotherapy for prostate cancer. Urology. 1994 Nov; 44(5):711-8.
    View in: PubMed
    Score: 0.009
  70. Treatment related sequelae following external beam radiation for prostate cancer: a review with an update in patients with stages T1 and T2 tumor. J Urol. 1994 Nov; 152(5 Pt 2):1799-805.
    View in: PubMed
    Score: 0.009
  71. Serum prostate-specific antigen after radiation therapy for clinically localized prostate cancer: prognostic implications. Int J Radiat Oncol Biol Phys. 1994 Sep 30; 30(2):279-87.
    View in: PubMed
    Score: 0.009
  72. Influence of initial presentation on treatment outcome of clinically localized prostate cancer treated by definitive radiation therapy. Int J Radiat Oncol Biol Phys. 1994 Sep 30; 30(2):331-7.
    View in: PubMed
    Score: 0.009
  73. Serum prostate-specific antigen, clinical stage, pathologic grade, and the incidence of nodal metastases in prostate cancer. Urology. 1994 Aug; 44(2):215-20.
    View in: PubMed
    Score: 0.009
  74. Prostate specific antigen doubling time and disease relapse after radiotherapy for prostate cancer. Cancer. 1994 Jul 15; 74(2):670-8.
    View in: PubMed
    Score: 0.009
  75. Near-diploidy: a new prognostic factor for clinically localized prostate cancer treated with external beam radiation therapy. Cancer. 1994 Apr 01; 73(7):1895-903.
    View in: PubMed
    Score: 0.009
  76. Dedifferentiation of locally recurrent prostate cancer after radiation therapy. Evidence for tumor progression. Cancer. 1993 Jun 01; 71(11):3783-7.
    View in: PubMed
    Score: 0.008
  77. Complications following external beam radiation therapy for prostate cancer: an analysis of patients treated with and without staging pelvic lymphadenectomy. J Urol. 1991 Sep; 146(3):798-802.
    View in: PubMed
    Score: 0.007
  78. The role of serum prostatic acid phosphatase in the management of adenocarcinoma of the prostate with radiotherapy. Int J Radiat Oncol Biol Phys. 1990 Dec; 19(6):1383-8.
    View in: PubMed
    Score: 0.007
  79. Radiation therapy of stage C prostate cancer: significance of Gleason grade to survival. Semin Urol. 1990 Nov; 8(4):225-31.
    View in: PubMed
    Score: 0.007
  80. Systemic hemibody irradiation for overt and occult metastases. Cancer. 1985 May 01; 55(9 Suppl):2210-21.
    View in: PubMed
    Score: 0.001
  81. Single-dose half-body irradiation for the palliation of multiple bone metastases from solid tumors: a preliminary report. Int J Radiat Oncol Biol Phys. 1981 Jun; 7(6):773-81.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.